Abstract | BACKGROUND: METHODS: RESULTS: Twenty patients were included by the end of this study. Muscular weakness, cramps, extremity paresthesia, Chovestek's sign and Trousseau's sign were relieved in 76.9%, 100%, 94.4%, 93.3% and 78.9% of patients, respectively. Serum calcium, plasma ionized calcium and serum phosphorus levels were (1.54+/-0.25) mmol/L, (0.64+/-0.10) mmol/L and (2.00+/-0.46) mmol/L at baseline, and reached (2.20+/-0.20) mmol/L, (0.95+/-0.06) mmol/L and (1.68+/-0.25) mmol/L (P<0.01) at the 12th week of treatment, respectively. Eighty percent of patients were assessed as effective and 20% as partly effective. Three, four and eight patients had hypercalciuria at the 4th, 8th and 12th week of treatment, respectively, which were reduced by thiazide diuretics. The final dose of calcitriol was (1.09+/-0.50) microg/d. CONCLUSIONS:
|
Authors | Ou Wang, Xiao-ping Xing, Xun-wu Meng, Wei-bo Xia, Mei Li, Yan Jiang, Ying-ying Hu, Huai-cheng Liu |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 122
Issue 3
Pg. 279-83
(Feb 05 2009)
ISSN: 2542-5641 [Electronic] China |
PMID | 19236804
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Calcitriol
(adverse effects, therapeutic use)
- Calcium
(blood, urine)
- Female
- Humans
- Hypocalcemia
(blood, drug therapy, etiology, urine)
- Hypoparathyroidism
(blood, complications, urine)
- Male
- Middle Aged
- Prospective Studies
- Pseudohypoparathyroidism
(blood, complications, urine)
|